- Home
- ESPR vs MLAC Comparison
ESPR vs MLAC Comparison
Compare ESPR & MLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- MLAC
- Stock Information
- Founded
- ESPR 2008
- MLAC 2024
- Country
- ESPR United States
- MLAC United States
- Employees
- ESPR N/A
- MLAC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- MLAC
- Sector
- ESPR Health Care
- MLAC
- Exchange
- ESPR Nasdaq
- MLAC NYSE
- Market Cap
- ESPR 305.0M
- MLAC 309.8M
- IPO Year
- ESPR 2013
- MLAC 2024
- Fundamental
- Price
- ESPR $1.69
- MLAC $10.04
- Analyst Decision
- ESPR Buy
- MLAC
- Analyst Count
- ESPR 7
- MLAC 0
- Target Price
- ESPR $6.36
- MLAC N/A
- AVG Volume (30 Days)
- ESPR 4.2M
- MLAC 8.0K
- Earning Date
- ESPR 03-04-2025
- MLAC 01-01-0001
- Dividend Yield
- ESPR N/A
- MLAC N/A
- EPS Growth
- ESPR N/A
- MLAC N/A
- EPS
- ESPR N/A
- MLAC N/A
- Revenue
- ESPR $332,314,000.00
- MLAC N/A
- Revenue This Year
- ESPR $5.51
- MLAC N/A
- Revenue Next Year
- ESPR $1.42
- MLAC N/A
- P/E Ratio
- ESPR N/A
- MLAC N/A
- Revenue Growth
- ESPR 185.66
- MLAC N/A
- 52 Week Low
- ESPR $1.47
- MLAC $9.94
- 52 Week High
- ESPR $3.94
- MLAC $10.17
- Technical
- Relative Strength Index (RSI)
- ESPR 49.78
- MLAC N/A
- Support Level
- ESPR $1.47
- MLAC N/A
- Resistance Level
- ESPR $1.61
- MLAC N/A
- Average True Range (ATR)
- ESPR 0.12
- MLAC 0.00
- MACD
- ESPR 0.02
- MLAC 0.00
- Stochastic Oscillator
- ESPR 56.41
- MLAC 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About MLAC MOUNTAIN LAKE ACQUISITION CORP
Mountain Lake Acquisition Corp is a blank check company.